<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00226278</url>
  </required_header>
  <id_info>
    <org_study_id>28130</org_study_id>
    <nct_id>NCT00226278</nct_id>
  </id_info>
  <brief_title>Safety Study of ORG 34517 for Major Depression With Psychotic Features</brief_title>
  <official_title>Prospective, Double Blind, Randomized, Placebo-Controlled Dose Finding Study of the Efficacy and Safety of 2 Target Doses of Org 34517 Used as Adjunct&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <brief_summary>
    <textblock>
      Patients suffering from Major Depressive Disorder with Psychotic features who have received
      no changes in their medications in the previous two weeks will receive &quot;usual&quot; treatment of
      antidepressants, antipsychotics and/or mood stabilizers and adjunct therapy using ORG34517.
      The patient will be hospitalized for up to two weeks to monitor their medications and
      progress and will return to the site for periodic assessments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Psychotic Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORG 34517</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  provide voluntary written informed consent for trial participation after the scope and
             nature of the investigation have been explained to them, and before starting any trial
             related activities

          -  be able to speak, read, understand, respond to questions and follow instructions in
             English

          -  have a DSM-IV severe depressive episode with psychotic features, as diagnosed by the
             MINI for single or recurrent episodes

          -  have a score on PANSS item &quot;Delusions&quot; AND/OR &quot;Hallucinatory behavior&quot; of at least 4
             at screening and baseline

          -  have a PANSS Positive Scale score of at least 16 at screening and baseline

          -  have a total score of at least 18 on teh HAMD 17 item scale at Screening and Baseline

          -  be on a stable dose of usual treatment which has to consist of an anti-depressant, an
             antipsychotic, a mood stabilizer or any combination of these three drug classes

          -  be 18 up to and including 70 years of age at Screening

          -  must be willing to be hospitalized for at least 11 days from Screening onwards.

        Exclusion Criteria:

          -  have any other psychiatric diagnosis except MDD

          -  have a lifetime psychiatric diagnosis of Bipolar Disorder I, schizophrenia or
             schizoaffective disorders

          -  are at significant risk of committing suicide

          -  are currently treated with carbamazepine or valproate

          -  are currently treated with midazolam

          -  have been treated with electroconvulsive therapy in the current episode

          -  are currently treated with more than one antidepressant

          -  are currently treated with more than one antipsychotic

          -  are currently treated with more than one mood stabilizer

          -  have usual treatment started or discontinued in the two weeks before randomization

          -  have a usual treatment dose change within the week prior to randomization

          -  have any clinically unstable or uncontrollable renal, hepatic, respiratory,
             haematological, cardiovascular or cerebrovascular disease that would put the patient
             at risk of safety or bias assessment efficacy

          -  have known hypersensitivity reactions to glucocorticoid antagonists

          -  have any clinically significant abnormal laboratory data

          -  have any untreated or uncompensated clinically significant endocrine disorder

          -  have a diagnosis or alcohol and/or drug dependence

          -  have a confirmed positive result on the drug screening test for any illicit drug
             except cannabis

          -  are using hormone replacement therapy at Screening

          -  require concomitant treatment with corticosteroids

          -  are subjects diagnosed with Cushing disease

          -  are women of childbearing potential without adequate contraception

          -  are women with a positive pregnancy test at screening or baseline or are breastfeeding
             mothers

          -  are male subjects with current diagnosis of prostrate hypertrophia or past history of
             symptoms of prostrate hypertrophia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James H Kocsis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College/New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2005</study_first_submitted>
  <study_first_submitted_qc>September 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2005</study_first_posted>
  <last_update_submitted>March 28, 2008</last_update_submitted>
  <last_update_submitted_qc>March 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2008</last_update_posted>
  <responsible_party>
    <name_title>James H. Kocsis, MD</name_title>
    <organization>Weill Cornell Medical College</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

